Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin
- PMID: 7907609
- PMCID: PMC501755
- DOI: 10.1136/jcp.47.1.43
Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin
Abstract
Aims: To provide a detailed knowledge of the distribution of the CD13 molecule, also known as the protease aminopeptidase-N, on both normal tissues and malignant neoplasms of epithelial and lymphoid origin.
Methods: CD13 antigen was examined by immunocytochemistry, using a recently produced antibody (VS5E) alongside a commercially available anti-CD13 monoclonal antibody. The VS5E recognising CD13 was produced by immunising a doxorubicin resistant breast cancer cell line (MCF-7-ADr). A striking feature of this antibody was that it stained the doxorubicin resistant cells but not the parental cell line. Both antibodies were tested on a broad range of normal tissues and three common types of epithelial malignancy (colon n = 28, lung n = 30, breast n = 35), and 12 cases of Hodgkin's and 52 of non-Hodgkin's lymphomas.
Results: CD13 was expressed on many tissue and cell types outside the haematopoietic system. In particular it was present on breast epithelium and in 20% (seven of 35) of breast carcinomas, but absent in normal and neoplastic colonic and bronchial tissues and lymphomas.
Conclusions: This study provides not only detailed information about the expression of the CD13 antigen, but also raises the important possibility that CD13 expression may correlate with drug resistance in breast carcinomas.
Similar articles
-
Expression of aminopeptidase N (CD13) in mesenchymal tumors.Am J Pathol. 1990 Nov;137(5):1215-22. Am J Pathol. 1990. PMID: 1978569 Free PMC article.
-
CD68 reactivity of non-macrophage derived tumours in cytological specimens.J Clin Pathol. 1993 Apr;46(4):334-6. doi: 10.1136/jcp.46.4.334. J Clin Pathol. 1993. PMID: 7684403 Free PMC article.
-
Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67.Br J Haematol. 1993 Mar;83(3):370-83. doi: 10.1111/j.1365-2141.1993.tb04659.x. Br J Haematol. 1993. PMID: 7683483
-
Monoclonal antibodies as diagnostic reagents for the identification and characterization of human tumor antigens.Prog Clin Pathol. 1984;9:121-33. Prog Clin Pathol. 1984. PMID: 6364219 Review. No abstract available.
-
Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!Blood. 1993 Aug 15;82(4):1052-70. Blood. 1993. PMID: 8102558 Review. No abstract available.
Cited by
-
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.Invest New Drugs. 2008 Jun;26(3):195-204. doi: 10.1007/s10637-007-9092-1. Epub 2007 Oct 6. Invest New Drugs. 2008. PMID: 17922077
-
CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications.Virchows Arch. 2022 Jun;480(6):1223-1230. doi: 10.1007/s00428-022-03304-9. Epub 2022 Feb 25. Virchows Arch. 2022. PMID: 35212813 Free PMC article.
-
Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor-α.Pharmaceutics. 2022 Jul 6;14(7):1414. doi: 10.3390/pharmaceutics14071414. Pharmaceutics. 2022. PMID: 35890309 Free PMC article. Review.
-
Proteome analysis of multidrug-resistant, breast cancer-derived microparticles.J Extracell Vesicles. 2014 Aug 22;3. doi: 10.3402/jev.v3.24384. eCollection 2014. J Extracell Vesicles. 2014. PMID: 25206959 Free PMC article.
-
Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells.Front Pharmacol. 2021 May 11;12:660377. doi: 10.3389/fphar.2021.660377. eCollection 2021. Front Pharmacol. 2021. PMID: 34045966 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous